pharmaphorum
JULY 28, 2022
Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease. Transgenic mice in which the gene has been deleted have improved control of blood glucose and insulin sensitivity.
The Pharma Data
APRIL 11, 2023
Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread.
The Pharma Data
JANUARY 21, 2021
Four years ago, the University of Malta established a national ALS Registry and Biobank to identify ALS patients and collect data on their residence, occupation, lifestyle and environmental exposures. Specifically, the Malta patients did not have mutations in the C9orf72, SOD1, TARDBP and FUS genes.
Expert insights. Personalized for you.
52 
Let's personalize your content